20 research outputs found

    Non-commutative hypergroup of order five

    Get PDF
    We prove that all hypergroups of order four are commutative and that there exists a non-comutative hypergroup of order five. These facts imply that the minimum order of non-commutative hypergroups is five even though the minimum order of non-commutative groups is six

    Non-commutative hypergroup of order five

    Get PDF
    We prove that all hypergroups of order four are commutative and that there exists a non-comutative hypergroup of order five. These facts imply that the minimum order of non-commutative hypergroups is five, even though the minimum order of non-commutative groups is six.ArticleJournal of Algebra and Its Applications.16(7):1750127(2016)journal articl

    Down regulation by a low-zinc diet in gene expression of rat prostatic thymidylate synthase and thymidine kinase

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Zinc has a wide spectrum of biological activities and its deficiency is related to various abnormalities of cell metabolism.</p> <p>Methods</p> <p>Wistar male rats, at age of 4 weeks, were fed a low-zinc diet for six weeks. The levels of bromodeoxyuridine incorporated into the prostatic DNA and the mRNA expression levels of prostate thymidylate synthase and thymidine kinase were examined.</p> <p>Result</p> <p>The low-zinc diet caused a marked reduction in the body growth and organ weights, resulted in a low hematopoiesis, hypo-albuminemia and hypocholesterolemia. Although there were few differences in plasma biochemical markers, plasma levels of luteinizing hormone and testosterone were reduced by the low-zinc diet. Bromodeoxyuridine-immunoreactive (S-phase) cells and mRNA expression levels of thymidylate synthase and thymidine kinase in the prostate cells were markedly affected by the low-zinc diet.</p> <p>Conclusion</p> <p>A low-zinc diet appears to reduce the body growth and organ weights including prostate, causing low plasma levels of luteinizing hormone and testosterone and reduction in prostate DNA replication in growing-rats.</p

    A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers

    Full text link
    This single-center retrospective observational study aimed to identify risk factors for developing denosumab-related osteonecrosis of the jaw (DRONJ) in stage IV solid cancer patients with bone metastases. In total, 123 consecutive patients who had received 120 mg of denosumab every 4 weeks at least twice between July 2014 and October 2018 were included. We surveyed their demographics, medical history, blood test, underlying disease, and intraoral findings. Fourteen patients (11.4%) developed DRONJ within a mean denosumab administration period of 4 months (range: 2&ndash;52 months). Univariate analyses showed a statistically significant correlation between DRONJ and hormone therapy, chemotherapy/molecular target drug, apical periodontitis, periodontal disease, sex and body mass index. Multivariate analysis showed a statistically significant correlation between DRONJ and hormone therapy (odds ratio [OR], 22.07; 95% confidence interval [CI], 2.86&ndash;170.24), chemotherapy and/or molecular targeted therapy (OR, 18.61; 95% CI, 2.54&ndash;136.27), and apical periodontitis (OR, 22.75; 95% CI, 3.20&ndash;161.73). These findings imply that collaborative oral examinations by oral specialists may reduce the risk of development of DRONJ in patients treated with denosumab for bone metastases from solid cancers
    corecore